Exelixis marked a 1.9% change today, compared to 1.0% for the S&P 500. Is it a good value at today's price of $19.61? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
-
Exelixis belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 24.45 and an average price to book (P/B) of 4.16
-
The company's P/B ratio is 2.48
-
Exelixis has a trailing 12 month Price to Earnings (P/E) ratio of 39.2 based on its trailing 12 month price to earnings (EPS) of $0.5 per share
-
Its forward P/E ratio is 21.1, based on its forward earnings per share (EPS) of $0.93
-
EXEL has a Price to Earnings Growth (PEG) ratio of 0.66, which shows the company is very undervalued compared to its earnings growth estimates.
-
Over the last four years, Exelixis has averaged free cash flows of $376.63 Million, which on average grew 0.0%
-
Over the last four years the company's operating margins have averaged 28.3 % and during this time they had a growth rate of -16.5 % and a coefficient of variability of 56.6 %.
-
Exelixis has moved 18.0% over the last year compared to 11.0% for the S&P 500 -- a difference of 7.0%
-
EXEL has an average analyst rating of buy and is -23.87% away from its mean target price of $25.76 per share
